{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T12:19:35Z","timestamp":1682511575437},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T00:00:00Z","timestamp":1429574400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s11936-015-0383-0","type":"journal-article","created":{"date-parts":[[2015,4,20]],"date-time":"2015-04-20T05:19:16Z","timestamp":1429507156000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel Antiplatelet Agents in Cardiovascular Medicine"],"prefix":"10.1007","volume":"17","author":[{"given":"Rahil","family":"Rafeedheen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin P.","family":"Bliden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,21]]},"reference":[{"key":"383_CR1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1586\/14779072.2.4.535","volume":"2","author":"PA Gurbel","year":"2004","unstructured":"Gurbel PA, Bliden KP, Hayes KM, et al. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther. 2004;2:535\u201345.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"383_CR2","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","volume":"357","author":"G Dav\u00ec","year":"2007","unstructured":"Dav\u00ec G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482\u201394.","journal-title":"N Engl J Med"},{"key":"383_CR3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.109.853085","volume":"121","author":"PA Gurbel","year":"2010","unstructured":"Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation. 2010;121:569\u201383.","journal-title":"Circulation"},{"key":"383_CR4","unstructured":"Use of aspirin for primary prevention of heart attack and stroke. http:\/\/www.fda.gov\/Drugs\/ResourcesForYou\/Consumers\/ucm390574.htm . Accessed 9 Feb 2015."},{"key":"383_CR5","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","volume":"107","author":"PA Gurbel","year":"2003","unstructured":"Gurbel PA, Bliden KP, Hiatt BL, O\u2019Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908\u201313.","journal-title":"Circulation"},{"key":"383_CR6","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/CIRCULATIONAHA.111.031195","volume":"125","author":"PA Gurbel","year":"2012","unstructured":"Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation. 2012;125:1276\u201387. discussion 1287.","journal-title":"Circulation"},{"key":"383_CR7","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","volume":"62","author":"US Tantry","year":"2013","unstructured":"Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261\u201373.","journal-title":"J Am Coll Cardiol"},{"key":"383_CR8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/erc.13.20","volume":"11","author":"US Tantry","year":"2013","unstructured":"Tantry US, Jeong YH, Navarese EP, Kubica J, Gurbel PA. Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. Expert Rev Cardiovasc Ther. 2013;11:447\u201362.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"383_CR9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","volume":"29","author":"L Wallentin","year":"2008","unstructured":"Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21\u201330.","journal-title":"Eur Heart J"},{"key":"383_CR10","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1517\/14656566.2012.704909","volume":"13","author":"YH Jeong","year":"2012","unstructured":"Jeong YH, Tantry US, Gurbel PA. Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel. Expert Opin Pharmacother. 2012;13:1771\u201396.","journal-title":"Expert Opin Pharmacother"},{"key":"383_CR11","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357. Landmark trial of ticagrelor therapy that leads to its recommendation by guidelines.","journal-title":"N Engl J Med"},{"key":"383_CR12","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315. Landmark trial of prasugrel therapy that leads to its recommendation by guidelines.","journal-title":"N Engl J Med"},{"key":"383_CR13","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jacc.2009.05.025","volume":"54","author":"M O\u2019Donoghue","year":"2009","unstructured":"O\u2019Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb\/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009;54:678\u201385.","journal-title":"J Am Coll Cardiol"},{"key":"383_CR14","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","volume":"367","author":"MT Roe","year":"2012","unstructured":"Roe MT, Armstrong PW, Fox KA, TRILOGY ACS Investigators, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297\u2013309.","journal-title":"N Engl J Med"},{"key":"383_CR15","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","volume":"369","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Bolognese L, Dudek D, ACCOAST Investigators, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999\u20131010.","journal-title":"N Engl J Med"},{"key":"383_CR16","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1517\/14656566.2010.511175","volume":"11","author":"PA Gurbel","year":"2010","unstructured":"Gurbel PA, Kereiakes DJ, Tantry US. Ticagrelor for the treatment of arterial thrombosis. Expert Opin Pharmacother. 2010;11:2251\u20139.","journal-title":"Expert Opin Pharmacother"},{"key":"383_CR17","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"PA Gurbel","year":"2009","unstructured":"Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study. Circulation. 2009;120:2577\u201385.","journal-title":"Circulation"},{"key":"383_CR18","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","volume":"121","author":"PA Gurbel","year":"2010","unstructured":"Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121:1188\u201399.","journal-title":"Circulation"},{"key":"383_CR19","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","volume":"124","author":"KW Mahaffey","year":"2011","unstructured":"Mahaffey KW, Wojdyla DM, Carroll K, PLATO Investigators, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544\u201354.","journal-title":"Circulation"},{"key":"383_CR20","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","volume":"371","author":"G Montalescot","year":"2014","unstructured":"Montalescot G, van\u2019t Hof AW, Lapostolle F, ATLANTIC Investigators, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371:1016. Highlighted the effect of timing of ticagrelor administration.","journal-title":"N Engl J Med"},{"key":"383_CR21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","volume":"382","author":"GW Stone","year":"2013","unstructured":"Stone GW, Witzenbichler B, Weisz G, ADAPT-DES Investigators, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382:614\u201323.","journal-title":"Lancet"},{"key":"383_CR22","unstructured":"Kirtane A. New insights into high platelet reactivity and the existence of a therapeutic window: ADAPT-DES at 2\u00a0years. Presented at TCT 2013 [cited 2014 Jan 24]. 2014. http:\/\/www.tctconference.com\/about-tct\/faculty.html?task=lecturer&sid=2146 ."},{"key":"383_CR23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.recesp.2014.01.013","volume":"67","author":"PA Gurbel","year":"2014","unstructured":"Gurbel PA, Rafeedheen R, Tantry US. Personalized antiplatelet therapy. Rev Esp Cardiol (Engl Ed). 2014;67:480\u20137.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"383_CR24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1185\/03007995.2014.880050","volume":"30","author":"J Kubica","year":"2014","unstructured":"Kubica J, Kozinski M, Navarese EP, et al. Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Curr Med Res Opin. 2014;30:813\u201328.","journal-title":"Curr Med Res Opin"},{"key":"383_CR25","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","volume":"361","author":"RA Harrington","year":"2009","unstructured":"Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361:2318\u201329.","journal-title":"N Engl J Med"},{"key":"383_CR26","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","volume":"361","author":"DL Bhatt","year":"2009","unstructured":"Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361:2330\u201341.","journal-title":"N Engl J Med"},{"key":"383_CR27","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303\u201313.","journal-title":"N Engl J Med"},{"key":"383_CR28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","volume":"163","author":"HD White","year":"2012","unstructured":"White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012;163:182\u201390.","journal-title":"Am Heart J"},{"key":"383_CR29","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1517\/13543784.2011.606809","volume":"20","author":"PA Gurbel","year":"2011","unstructured":"Gurbel PA, Jeong YH, Tantry US. Vorapaxar: a novel protease-activated receptor-1 inhibitor. Expert Opin Investig Drugs. 2011;20:1445\u201353.","journal-title":"Expert Opin Investig Drugs"},{"key":"383_CR30","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","volume":"382","author":"PG Steg","year":"2013","unstructured":"Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382:1981\u201392.","journal-title":"Lancet"},{"key":"383_CR31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","volume":"307","author":"DJ Angiolillo","year":"2012","unstructured":"Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery. JAMA. 2012;307:265\u201374.","journal-title":"JAMA"},{"key":"383_CR32","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/CIRCINTERVENTIONS.111.964197","volume":"5","author":"RC Welsh","year":"2012","unstructured":"Welsh RC, Rao SV, Zeymer U, et al. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012;5:336\u201346.","journal-title":"Circ Cardiovasc Interv"},{"key":"383_CR33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C, TRACER Investigators, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20\u201333.","journal-title":"N Engl J Med"},{"key":"383_CR34","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP, TRA 2P\u2013TIMI 50 Steering Committee and Investigators, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404\u201313.","journal-title":"N Engl J Med"},{"key":"383_CR35","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","volume":"380","author":"BM Scirica","year":"2012","unstructured":"Scirica BM, Bonaca MP, Braunwald E, TRA 20P-TIMI 50 Steering Committee Investigators, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 20P-TIMI 50 trial. Lancet. 2012;380:1317\u201324. Important retrospective analysis of vorapaxar trial that is responsible for its recommendation.","journal-title":"Lancet"},{"key":"383_CR36","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1021\/jm400820m","volume":"56","author":"P Bach","year":"2013","unstructured":"Bach P, Antonsson T, Bylund R, et al. Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. Separation of the antithrombotic effect and bleeding for candidate drug AZD1283. J Med Chem. 2013;56:7015\u201324.","journal-title":"J Med Chem"},{"key":"383_CR37","volume":"9","author":"H Chang","year":"2014","unstructured":"Chang H, Yanachkov IB, Dix EJ, et al. Antiplatelet activity, P2Y1 and P2Y12 inhibition, and metabolism in plasma of stereoisomers of diadenosine 5\u2032,5\u2032\u2033-P1, P4-dithio-P2, P3-chloromethylenetetraphosphate. PLoS One. 2014;9, e94780.","journal-title":"PLoS One"},{"key":"383_CR38","volume-title":"Antiplatelet therapy in cardiovascular disease","author":"P Zhang","year":"2014","unstructured":"Zhang P, Covic L, Kuliopulos A. Platelet receptors and drug targets: PAR1, collagen, vWF, thromboxane, and other novel targets. In: Waksman R, Gurbel PA, Giglia MA, editors. Antiplatelet therapy in cardiovascular disease. West Susses: Wiley; 2014."},{"key":"383_CR39","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nm760","volume":"8","author":"L Covic","year":"2002","unstructured":"Covic L, Misra M, Badar J, Singh C, Kuliopulos A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med. 2002;8:1161\u20135.","journal-title":"Nat Med"},{"key":"383_CR40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.112.091918","volume":"126","author":"P Zhang","year":"2012","unstructured":"Zhang P, Gruber A, Kasuda S, et al. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation. 2012;126:83\u201391.","journal-title":"Circulation"},{"issue":"Suppl 3","key":"383_CR41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000209262","volume":"27","author":"A Chamorro","year":"2009","unstructured":"Chamorro A. TP receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc Dis. 2009;27 Suppl 3:20\u20137.","journal-title":"Cerebrovasc Dis"},{"key":"383_CR42","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(11)60600-4","volume":"377","author":"MG Bousser","year":"2011","unstructured":"Bousser MG, Amarenco P, Chamorro A, PERFORM Study Investigators, et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet. 2011;377:2013\u201322.","journal-title":"Lancet"},{"key":"383_CR43","first-page":"93","volume":"3","author":"A Celestini","year":"2007","unstructured":"Celestini A, Violi F. A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vasc Health Risk Manag. 2007;3:93\u20138.","journal-title":"Vasc Health Risk Manag"},{"key":"383_CR44","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1160\/TH09-09-0635","volume":"103","author":"S Basili","year":"2010","unstructured":"Basili S, Raparelli V, Vestri A, et al. Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis. Thromb Haemost. 2010;103:766\u201373.","journal-title":"Thromb Haemost"},{"key":"383_CR45","doi-asserted-by":"crossref","unstructured":"Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2\/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation. 1994;89:588\u201395.","DOI":"10.1161\/01.CIR.89.2.588"},{"key":"383_CR46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2125.2004.02083.x","volume":"58","author":"BD Guth","year":"2004","unstructured":"Guth BD, Narjes H, Schubert HD, et al. Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects. Br J Clin Pharmacol. 2004;58:40\u201351.","journal-title":"Br J Clin Pharmacol"},{"key":"383_CR47","unstructured":"Combe S, Rosport K, Kennedy A. PR-15 A novel intravenous inhibitor of platelet adhesion: a phase I dose ascending pharmacokinetic, pharmacodynamic, and tolerance study. J Thromb Haemost 2007;5 (Suppl 2) Abstract P-T-683"},{"key":"383_CR48","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1096\/fj.03-0464fje","volume":"18","author":"S Massberg","year":"2004","unstructured":"Massberg S, Konrad I, Bultmann A, et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J. 2004;18:397\u20139.","journal-title":"FASEB J"},{"key":"383_CR49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071193","volume":"8","author":"M Ungerer","year":"2013","unstructured":"Ungerer M, Li Z, Baumgartner C, et al. The GPVI-Fc fusion protein revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times. PLoS One. 2013;8, e71193.","journal-title":"PLoS One"},{"key":"383_CR50","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.110.980623","volume":"123","author":"M Ungerer","year":"2011","unstructured":"Ungerer M, Rosport K, B\u00fcltmann A, et al. Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation. 2011;123:1891\u20139.","journal-title":"Circulation"},{"key":"383_CR51","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nm1232","volume":"11","author":"SP Jackson","year":"2005","unstructured":"Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005;11:507\u201314.","journal-title":"Nat Med"},{"key":"383_CR52","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/blood-2009-04-217224","volume":"115","author":"V Martin","year":"2010","unstructured":"Martin V, Guillermet-Guibert J, Chicanne G, et al. Deletion of the p110b isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood. 2010;115:2008\u201313.","journal-title":"Blood"},{"key":"383_CR53","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/j.1538-7836.2012.04912.x","volume":"10","author":"SP Jackson","year":"2012","unstructured":"Jackson SP, Schoenwaelder SM. Antithrombotic phosphoinositide 3-kinase \u03b2 inhibitors in humans: a \u2018shear\u2019 delight! J Thromb Haemost. 2012;10:2123\u20136.","journal-title":"J Thromb Haemost"},{"key":"383_CR54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.bjp.0706711","volume":"148","author":"T Uemura","year":"2006","unstructured":"Uemura T, Kawasaki T, Taniguchi M, et al. Biological properties of a specific Galpha q\/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress. Br J Pharmacol. 2006;148:61\u20139.","journal-title":"Br J Pharmacol"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-015-0383-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-015-0383-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-015-0383-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T19:59:18Z","timestamp":1566590358000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-015-0383-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,21]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["383"],"URL":"https:\/\/doi.org\/10.1007\/s11936-015-0383-0","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,21]]},"article-number":"23"}}